Form 4: CEO Quinn Boosts BOLT Stake, Receives New Stock Options

Bolt Biotherapeutics' President, CEO, and CFO, William P. Quinn, reported an acquisition of common stock and a grant of 20,000 employee stock options.

Summary

• William P. Quinn, President, CEO, and CFO of Bolt Biotherapeutics, Inc. (BOLT), acquired 125 shares of common stock on December 5, 2025, at a price of $4.607 per share.
• The common stock acquisition was made under the Issuer's Employee Stock Purchase Plan (ESPP) and is exempt under Rule 16b-3(c).
• Following this transaction, Quinn beneficially owns 2,313 shares of common stock directly.
• Quinn was granted 20,000 employee stock options on January 28, 2026, with an exercise price of $6.71 per share.
• These options will vest at a rate of 1/36th of the shares per month of continuous service following January 1, 2026, and expire on January 27, 2036.
• Following the option grant, Quinn beneficially owns 20,000 derivative securities directly.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as moderately positive. While the transactions are routine, the insider purchase and option grant demonstrate management's continued commitment and alignment with shareholder interests, which is generally a favorable signal.

Positives

• The acquisition of 125 shares of common stock by the CEO, even if small, represents an insider purchase, which can signal management's confidence in the company's future.
• The grant of 20,000 employee stock options aligns the CEO's long-term incentives with shareholder value creation, as the options gain value if the stock price increases.

Future Outlook

The vesting schedule for the granted stock options, tied to continuous service following January 1, 2026, indicates an expectation of William P. Quinn's continued tenure and commitment to Bolt Biotherapeutics for the foreseeable future.

Industry Context

StockSavvy.ai notes that insider purchases and stock option grants are common mechanisms for aligning management incentives with shareholder interests, particularly in the biotechnology sector where long-term development cycles necessitate sustained executive commitment. These actions are standard practices to retain key talent and motivate performance.

Comparison to Industry Standards

• StockSavvy.ai notes that participation in Employee Stock Purchase Plans (ESPPs) and the granting of stock options are standard components of executive compensation packages across the biotechnology industry, comparable to practices at companies like Amgen or Gilead Sciences.
• The vesting schedule for the options, tied to continuous service, is a common structure designed to incentivize long-term executive retention and performance, aligning with best practices observed in the broader market.

Stakeholder Impact

• Shareholders: The transactions align the CEO's financial interests with the company's performance, potentially benefiting shareholders through motivated leadership.
• Employees: The ESPP participation highlights a benefit available to employees, fostering a sense of shared ownership.

Next Steps

• William P. Quinn's continued service to the Issuer for the vesting of the granted stock options.

Key Dates

Recommendation

The filing details routine insider transactions, including an ESPP purchase and a stock option grant, which are standard compensation practices and do not provide new fundamental information to alter an investment thesis. These actions align management's interests with shareholders but do not signal a significant change in company outlook that would warrant a strong buy or sell recommendation based solely on this Form 4.

Keywords

Bolt Biotherapeutics, BOLT, William P. Quinn, Insider Trading, Form 4, Stock Options, ESPP, Common Stock, CEO, CFO, Director